Somryst® the first and only FDA authorized digital treatment for chronic insomnia using CBT (Cognitive Behavioral Therapy for Insomnia – CBTi) will currently be unavailable. This is due to its parent company Pear Therapeutics, Inc. has filed for a Chapter 11 bancruptcy on April 7, 2023. The debtors voluntarily filed for Chapter 11 bancruptcy protection in the United States Bancruptcy Court for the District of Delaware. The company is seeking to sell their assets through a sales process.
“Our hope is that our business and/or products will be purchased so that another company can provide them to patients. Pear Therapeutics is not accepting new prescriptions for its products, reSET®, reSET-O®, and Somryst®, nor will refills be dispensed at this time. We will attempt to keep our products available for patients who are already using the products for the duration of the current fill of their prescription, but there can be no assurance that we will be able to do so.”
For more information and updates you may visit their website at www.peartherapeutics.com.
Related Content
